written by reader PTN News Release: AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder

by 23Scadoo | January 9, 2017 8:20 am

Long $PTN

http://finance.yahoo.com/news/amag-pharmaceuticals-palatin-technologies-enter-130000071.html[1]

Endnotes:
  1. http://finance.yahoo.com/news/amag-pharmaceuticals-palatin-technologies-enter-130000071.html: http://finance.yahoo.com/news/amag-pharmaceuticals-palatin-technologies-enter-130000071.html

Source URL: https://www.stockgumshoe.com/2017/01/microblog-ptn-news-release-amag-pharmaceuticals-and-palatin-technologies-enter-into-exclusive-licensing-agreement-for-north-american-rights-to-rekyndatm-bremelanotide-a-potential-treatment-for/


One response to “written by reader PTN News Release: AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder”

  1. dcsorg says:

    Why is AMAG down $12.60 on minor news? Any insight on this issue. I have been watching this stock and considering buying, is there more to the issue. Could it be manipulation by larger players. Down 35% it a bit extreme. Any ideas.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.